Evaluation of the therapeutic effect of botulinum toxin type a in patients with rosacea erythema telangiectasia and analysis of dermoscopic characteristics
Objective To evaluate the therapeutic effect of botulinum toxin type A(BTX-A)in patients with rosacea erythema telangiectasia and analyze the characteristics of dermoscopy.Methods Thirty patients with erythema telangiectasia rosacea treated in our hospital from January 2021 to August 2023 were collected as the observation targets.All of them received oral drugs(doxycycline hydrochloride combined with hydroxychloroquine sulfate),and were randomized,double-blind,face-divided.The patients with rosacea were injected with botulinum toxin type A(treatment side)and normal saline(control side)respectively,and the skin physiological indexes(transepidermal water loss,oil content,cuticle water content,erythema index)of the patients before and after treatment were compared.The vascular changes before and after dermoscopic treatment were analyzed,and the incidence of adverse reactions of the patients were calculated.Results After treatment,compared with the control side,the water loss,erythema index and oil content in the epidermis of the treatment side were decreased,and the water content in the stratum corneum was increased after treatment,with statistical significance(P<0.05).There was no difference before and after treatment on the control side(P>0.05).On the treatment side,the therapeutic effect was the best at 4 weeks after treatment,and the effect lasted until the 8th week,with no statistical significance(P>0.05),and the therapeutic effect was weakened at 8 weeks to 12 weeks,with statistical significance(P<0.05).The results of dermoscopy showed that after 4 weeks of treatment,compared with before treatment,the distribution proportion of dark red background,red background and polygonal blood vessels decreased,while the distribution proportion of light red background,linear blood vessels,branched blood vessels and punctured blood vessels increased,with statistical significance(P<0.05).There were no significant differences in yellow and red background and blood vessel distribution(P>0.05).The incidence of adverse reactions was 6.67%in the control group and 10.00%in the treatment group,with no statistical difference between the two groups(P>0.05).Conclusion BTX-A has a significant improvement effect on the symptoms of erythematous telangiectatic rosacea with high safety.
Erythema telangiectasiaRosaceaBotulinum toxin Type ADermoscopy
国家科技期刊平台
NSTL
万方数据
